NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
Active Not RecruitingPhase 4
Sponsor: AstraZeneca
Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: olaparib, enzalutamide, abiraterone acetate, Prednisone
Countries: China
The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.
Eligibility overview
Sex: MALE
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Eligibility criteria
Inclusion criteria： 1. Histologically confirmed diagnosis of prostate cancer. 2. Documented evidence of metastatic castration resistant prostate cancer (mCRPC). 3. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC . 4. Ongoing therapy with LHRH analog or bilateral orchiectomy. 5. Radiological progression at study entry while on androgen deprivation therapy (or after bilateral orchiectomy). 6. Deleterious or suspected deleterious BRCA1/2 mutation in tumor tissue. 7. Normal organ and bone marrow function measured within 28 days prior to administration of study treatment. 8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing. Exclusion criteria： 1. Any previous treatment with a poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor, including olaparib. 2. Subjects who had any previous treatment with DNA-damaging cytotoxic chemotherapy, except if for non-prostate cancer indication and last dose \> 5 years prior to randomization. 3. History of another primary malignancy except for malignancy treated with curative intent with no known active disease for ≥5 years before the first dose of study intervention and of low potential risk for recurrence. 4. Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.
Locations (35)
- Beijing, China
- Bengbu, China
- Changsha, China
- Changsha, China
- Chengdu, China
- Chongqing, China
- Fuzhou, China
- Guangzhou, China
- Guangzhou, China
- Hangzhou, China
- Hangzhou, China
- Hangzhou, China
- Hefei, China
- Jiaxing, China
- Jinan, China
- Jinan, China
- Jining, China
- Kunming, China
- Lanzhou, China
- Linyi, China
- Nanchang, China
- Nantong, China
- Ningbo, China
- Shanghai, China
- Shanghai, China
- Shenyang, China
- Suzhou, China
- Taiyuan, China
- Tianjin, China
- Wanzhou, China
- + 5 more on CT.gov